Hubei Biocause Pharmaceutical (000627) - Total Assets

Latest as of September 2024: CN¥285.15 Billion CNY ≈ $41.73 Billion USD

Based on the latest financial reports, Hubei Biocause Pharmaceutical (000627) holds total assets worth CN¥285.15 Billion CNY (≈ $41.73 Billion USD) as of September 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Hubei Biocause Pharmaceutical - Total Assets Trend (2000–2023)

This chart illustrates how Hubei Biocause Pharmaceutical's total assets have evolved over time, based on quarterly financial data. Also see Hubei Biocause Pharmaceutical market capitalisation for the company's overall valuation and market capitalisation.

Hubei Biocause Pharmaceutical - Asset Composition Analysis

Current Asset Composition (December 2023)

Hubei Biocause Pharmaceutical's total assets of CN¥285.15 Billion consist of 16.8% current assets and 83.2% non-current assets. Review 000627 current and long-term liabilities to assess the company's total debt and financial obligations.

Asset Category	Amount (CNY)	% of Total Assets
Cash & Equivalents	CN¥0.00	9.3%
Accounts Receivable	CN¥77.20 Million	0.0%
Inventory	CN¥4.13 Billion	1.4%
Property, Plant & Equipment	CN¥0.00	0.0%
Intangible Assets	CN¥283.20 Million	0.1%
Goodwill	CN¥6.19 Billion	2.1%

Asset Composition Trend (2000–2023)

This chart illustrates how Hubei Biocause Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 000627 stock price and chart for real-time trading data and today's change.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Hubei Biocause Pharmaceutical's current assets represent 16.8% of total assets in 2023, an increase from 0.0% in 2000.
Cash Position: Cash and equivalents constituted 9.3% of total assets in 2023, down from 11.8% in 2000.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 11.0% in 2000.
Asset Diversification: The largest asset category is goodwill at 2.1% of total assets.

Hubei Biocause Pharmaceutical Competitors by Total Assets

Key competitors of Hubei Biocause Pharmaceutical based on total assets are shown below.

Company	Country	Total Assets
Globe Life Inc NYSE:GL	USA	$31.56 Billion
Challenger Ltd AU:CGF	Australia	AU$35.37 Billion
Brighthouse Financial Inc NASDAQ:BHF	USA	$244.68 Billion
Abacus Global Management, Inc. NYSE:ABX	USA	$867.73 Million
Clearview Wealth Ltd AU:CVW	Australia	AU$1.07 Billion
Nobleoak Life Ltd AU:NOL	Australia	AU$600.63 Million
Hapvida Participações e Investimentos S.A. SA:HAPV3	Brazil	R$72.99 Billion
Manulife Financial Corp TO:MFC	Canada	CA$1.03 Trillion

Hubei Biocause Pharmaceutical - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	2.02	2.08	3.06
Quick Ratio	1.80	1.91	2.62
Cash Ratio	0.00	0.00	0.00
Working Capital	CN¥17.75 Billion	CN¥24.66 Billion	CN¥17.35 Billion

Hubei Biocause Pharmaceutical - Advanced Valuation Insights

This section examines the relationship between Hubei Biocause Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	0.36
Latest Market Cap to Assets Ratio	0.00
Asset Growth Rate (YoY)	4.6%
Total Assets	CN¥301.94 Billion
Market Capitalization	$1.13 Billion USD

Valuation Analysis

Below Book Valuation: The market values Hubei Biocause Pharmaceutical's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Hubei Biocause Pharmaceutical's assets grew by 4.6% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Hubei Biocause Pharmaceutical (2000–2023)

The table below shows the annual total assets of Hubei Biocause Pharmaceutical from 2000 to 2023.

Year	Total Assets	Change
2023-12-31	CN¥301.94 Billion ≈ $44.18 Billion	+4.62%
2022-12-31	CN¥288.60 Billion ≈ $42.23 Billion	+9.36%
2021-12-31	CN¥263.90 Billion ≈ $38.62 Billion	+10.23%
2020-12-31	CN¥239.40 Billion ≈ $35.03 Billion	+16.63%
2019-12-31	CN¥205.27 Billion ≈ $30.04 Billion	+15.16%
2018-12-31	CN¥178.25 Billion ≈ $26.08 Billion	+26.95%
2017-12-31	CN¥140.42 Billion ≈ $20.55 Billion	+19.12%
2016-12-31	CN¥117.88 Billion ≈ $17.25 Billion	+4792.75%
2015-12-31	CN¥2.41 Billion ≈ $352.54 Million	+14.26%
2014-12-31	CN¥2.11 Billion ≈ $308.54 Million	-2.25%
2013-12-31	CN¥2.16 Billion ≈ $315.63 Million	+4.47%
2012-12-31	CN¥2.06 Billion ≈ $302.13 Million	+9.62%
2011-12-31	CN¥1.88 Billion ≈ $275.63 Million	-4.69%
2010-12-31	CN¥1.98 Billion ≈ $289.20 Million	-8.32%
2009-12-31	CN¥2.16 Billion ≈ $315.45 Million	+8.90%
2008-12-31	CN¥1.98 Billion ≈ $289.67 Million	+49.45%
2007-12-31	CN¥1.32 Billion ≈ $193.82 Million	+13.46%
2006-12-31	CN¥1.17 Billion ≈ $170.82 Million	+7.30%
2005-12-31	CN¥1.09 Billion ≈ $159.20 Million	+0.61%
2004-12-31	CN¥1.08 Billion ≈ $158.23 Million	-0.88%
2003-12-31	CN¥1.09 Billion ≈ $159.64 Million	+0.05%
2002-12-31	CN¥1.09 Billion ≈ $159.56 Million	+10.24%
2001-12-31	CN¥989.09 Million ≈ $144.73 Million	+11.59%
2000-12-31	CN¥886.33 Million ≈ $129.70 Million	--

About Hubei Biocause Pharmaceutical

SHE:000627 China Insurance - Life

Market Cap

$1.13 Billion

CN¥7.75 Billion CNY

Market Cap Rank

#8359 Global

#1946 in China

Share Price

CN¥1.58

Change (1 day)

+0.00%

52-Week Range

CN¥1.58 - CN¥1.58

All Time High

CN¥10.45